Long-term treatment of patients with Alzheimer's disease in primary and secondary care: results from an international survey

References

• Heese K, Akatsu H. Alzheimer’s disease – an interactive perspective. Curr Alzheimer Res 2006;3:109-21
   PubMedGoogle Scholar
• Leber PD Davis CS Threats to the validity of clinical trials employing enrichment strategies for sample selection. Control Clin Trials 1998;19:178-87
   PubMedGoogle Scholar
• Schneider LS, Olin JT, Lyness SA, et al. Eligibility of Alzheimer’s disease clinic patients for clinical trials. J Am Geriatr Soc 1997;45:923-8
   PubMed Web of Science ®Google Scholar
• Teri L. Behavior and caregiver burden: behavioral problems in patients with Alzheimer disease and its association with caregiver distress. Alzheimer Dis Assoc Disord 1997;11(Suppl. 4):S35-S38
   PubMedGoogle Scholar
• Diagnostic and Statistical Manual of Mental Disorders, Fourth Edn (DSM-IV). Washington, DC: American Psychiatric Association, 1994
   Google Scholar
• Folstein MF, Folstein SE, McHugh PR ‘Mini-mental state’: a practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res 1975;12:189-98
   PubMed Web of Science ®Google Scholar
• Gélinas I, Gauthier L, McIntyre M, et al. Development of a functional measure for persons with Alzheimer’s disease: the Disability Assessment for Dementia. Am J Occup Ther 1999;53:471-81
   PubMed Web of Science ®Google Scholar
• Cummings JL, Mega M, Gray K, et al. The Neuropsychiatric Inventory: comprehensive assessment of psychopathology in dementia. Neurology 1994;44:2308-14
   PubMed Web of Science ®Google Scholar
• Guy W, Bonato RR. Clinical Global Impressions Scale (CGI). From: Manual for the ECDEU Assessment Battery, Biometric Laboratory. Washington, DC: George Washington University, 1970
   Google Scholar
• Buysse DJ, Reynolds CFIII, Monk TH, et al. The Pittsburgh Sleep Quality Index: a new instrument for psychiatric practice and research. Psychiatry Res 1989;28:193-213
   PubMed Web of Science ®Google Scholar
• Zarit SH, Todd PA, Zarit JM Subjective burden of husbands and wives as caregivers: a longitudinal study. Gerontologist 1986;26:260-6
   PubMed Web of Science ®Google Scholar
• Han L, Cole M, Bellavance F, et al. Tracking cognitive decline in Alzheimer’s disease using the mini-mental state examination: a meta-analysis. Int Psychogeriatr 2000;12:231-47
   PubMed Web of Science ®Google Scholar
• Mendiondo MS, Ashford JW, Kryscio RJ, et al. Modelling mini mental state examination changes in Alzheimer’s disease. Stat Med 2000;19:1607-16
   PubMed Web of Science ®Google Scholar
• Feldman HH, Van BB, Kavanagh SM, et al. Cognition, function, and caregiving time patterns in patients with mild-to-moderate Alzheimer disease: a 12-month analysis. Alzheimer Dis Assoc Disord 2005;19:29-36
   PubMed Web of Science ®Google Scholar
• NICE. Donepezil, galantamine, rivastigmine (review) and memantine for the treatment of Alzheimer’s disease (amended). London: National Institute for Health and Clinical Excellence, 2007
   Google Scholar
• McCarten JR, Rottunda SJ, Kuskowski MA Change in the mini-mental state exam in Alzheimer’s disease over 2 years: the experience of a dementia clinic. J Alzheimers Dis 2004;6:11-15
   PubMed Web of Science ®Google Scholar
• Reisberg B. Global measures: utility in defining and measuring treatment response in dementia. Int Psychogeriatr 2007;19:421-56
   PubMed Web of Science ®Google Scholar
• Tang-Wai DF, Knopman DS, Geda YE, et al. Comparison of the short test of mental status and the mini-mental state examination in mild cognitive impairment. Arch Neurol 2003;60:1777-81
   PubMed Web of Science ®Google Scholar
• Jacqmin-Gadda H, Fabrigoule C, Commenges D, et al. A 5-year longitudinal study of the Mini-Mental State Examination in normal aging. Am J Epidemiol 1997;145:498-506
   PubMed Web of Science ®Google Scholar
• Lopez OL, Becker JT, Wisniewski S, et al. Cholinesterase inhibitor treatment alters the natural history of Alzheimer’s disease. J Neurol Neurosurg Psychiatry 2002;72:310-14
   PubMed Web of Science ®Google Scholar
• Lopez OL, Becker JT, Saxton J, et al. Alteration of a clinically meaningful outcome in the natural history of Alzheimer’s disease by cholinesterase inhibition. J Am Geriatr Soc 2005;53:83-7
   PubMed Web of Science ®Google Scholar
• Small GW, Kaufer D, Mendiondo MS, et al. Cognitive performance in Alzheimer’s disease patients receiving rivastigmine for up to 5 years. Int J Clin Pract 2005;59:473-7
   PubMed Web of Science ®Google Scholar
• Mittelman MS, Haley WE, Clay OJ, et al. Improving caregiver well-being delays nursing home placement of patients with Alzheimer disease. Neurology 2006;67:1592-9
   PubMed Web of Science ®Google Scholar
• Gold M. Study design factors and patient demographics and their effect on the decline of placebo-treated subjects in randomized clinical trials in Alzheimer’s disease. J Clin Psychiatry 2007;68:430-8
   PubMed Web of Science ®Google Scholar
• Reynish E, Cortes F, Andrieu S, et al. The ICTUS Study: a prospective longitudinal observational study of 1,380 AD patients in Europe. Study design and baseline characteristics of the cohort. Neuroepidemiology 2007;29:29-38
   PubMed Web of Science ®Google Scholar
• Wilcock GK, Lilienfeld S, Gaens E. Efficacy and safety of galantamine in patients with mild to moderate Alzheimer’s disease: multicentre randomised controlled trial. BMJ 2000;321:1445-9
   PubMed Web of Science ®Google Scholar
• Raskind MA, Peskind ER, Wessel T, et al. Galantamine in AD: a 6-month randomized, placebo-controlled trial with a 6-month extension. Neurology 2000;54:2261-8
   PubMed Web of Science ®Google Scholar
• Rockwood K, Mintzer J, Truyen L, et al. Effects of a flexible galantamine dose in Alzheimer’s disease: a randomised controlled trial. J Neurol Neurosurg Psychiatry 2001;71:589-95
   PubMed Web of Science ®Google Scholar
• Rowe MA, McCrae CS, Campbell JM, et al. Sleep pattern differences between older adult dementia caregivers and older adult noncaregivers using objective and subjective measures. J Clin Sleep 2008;4:362-9
   PubMed Web of Science ®Google Scholar
• Birks J. Cholinesterase inhibitors for Alzheimer’s disease. Cochrane Database Syst Rev 2006 Jan 25;(1):CD005593
   Google Scholar
• Feil D, Marmon T, Unützer J. Cognitive impairment, chronic mental illness, and risk of mortality in an elderly cohort. Am J Geriatr Psychiatry 2003;11:551-60
   PubMed Web of Science ®Google Scholar
• Wolfson C, Wolfson DB, Asgharian M, et al. A reevaluation of the duration of survival after the onset of dementia. N Engl J Med 2001;344:1111-16
   PubMed Web of Science ®Google Scholar
• Behl P, Lanctôt KL, Streiner DL, et al. The effect of cholinesterase inhibitors on decline in multiple functional domains in Alzheimer’s disease: a two-year observational study in the Sunnybrook dementia cohort. Int Psychogeriatr 2008;20:1141-59
   PubMed Web of Science ®Google Scholar
• Calabria M, Geroldi C, Lussignoli G, et al. Efficacy of acetyl-cholinesterase-inhibitor (ACHEI) treatment in Alzheimer’s disease: a 21-month follow-up ‘real world’ study. Arch Gerontol Geriatr 2009;49:e6-11
   PubMed Web of Science ®Google Scholar
• Vantelon C, Gilbert S, Kerneis S, et al. [Cholinesterase inhibitor therapy in long term care settings] [Article in French]. Rev Med Interne 2006;27:588-94
   PubMed Web of Science ®Google Scholar
• Irizarry MC, Webb DJ, Bains C, et al. Predictors of placebo decline in the Alzheimer’s disease Assessment Scale-Cognitive subscale (ADAS-Cog) in 24 week clinical trials of Alzheimer’s disease. J Alzheimers Dis 2008;14:301-11
   PubMed Web of Science ®Google Scholar
• Wallin ÅK, Andreasen N, Eriksson S, et al. Donepezil in Alzheimer’s disease: what to expect after 3 years of treatment in a routine clinical setting. Dement Geriatr Cogn Disord 2007;23:150-60
   PubMed Web of Science ®Google Scholar
• Minthon L, Wallin AK, Eriksson S, et al. Long-term rivastigmine treatment in a routine clinical setting. Acta Neurol Scand 2009;119:180-5
   PubMed Web of Science ®Google Scholar